Generate Biomedicines (NASDAQ:GENB) Reaches New 1-Year High – Here’s What Happened

Shares of Generate Biomedicines Inc (NASDAQ:GENB) hit a new 52-week high during trading on Tuesday . The company traded as high as $17.98 and last traded at $16.91, with a volume of 1704246 shares. The stock had previously closed at $16.47.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Guggenheim assumed coverage on shares of Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $30.00 target price on the stock. Morgan Stanley raised their price target on Generate Biomedicines from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. The Goldman Sachs Group began coverage on Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective for the company. Piper Sandler assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target for the company. Finally, HC Wainwright boosted their target price on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Six investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $25.40.

Generate Biomedicines Stock Down 2.2%

The stock’s fifty day moving average price is $14.02. The firm has a market capitalization of $2.12 billion and a price-to-earnings ratio of -15.42.

Generate Biomedicines (NASDAQ:GENB) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.